Tag Archives: Pharmaceutical

Innovation Upturn? New Medical Entities /$ Increasing!

A recent posting on Derek Lowe’s “In the Pipeline” presents a dismal view of the returns on R&D in Pharma.   BCG had included a graph (from Bernstein Research) of the trend of new molecular entities (“nme”) per $B spent over … Continue reading

Posted in Financial, Innovation, New R&D models | Tagged , | 4 Comments



McKinsey article hits close to home…

While I have been using the name “R&D Returns” for years, I welcome this article from McKinsey.  Here, they call attention to the value of balanced R&D architecture and management.  Some of the sea-change tools cited on my home page here … Continue reading

Posted in Financial, General Interest, Research | Tagged , , | Leave a comment



The R&D Returns “Ceiling”

BioPharma firms vary greatly in their ability to bring novel therapies to market – what causes some to underperform? Continue reading

Posted in General Interest, In the Pipeline | Tagged , , , | 3 Comments